Inhibition of cancer cell proliferation by 5-fluoro-2'-deoxycytidine, a DNA methylation inhibitor, through activation of DNA damage response pathway

SpringerPlus

Volumn 1, Issue 1, 2012, Pages 1-11

  Zhao, Quanyi ^a   Fan, Jiadong ^a   Hong, Wei ^a   Li, Lianyun ^a   Wu, Min ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Cancer; Cell cycle; DNA damage response; DNA methylation; FCdR; P53

Indexed keywords

EID: 84873489946     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-1-65     Document Type: Article

References (23)

1. Aylon Y, Oren M (2011) New plays in the p53 theater. Curr Opin Genet Dev 21:86-92
2. Beumer JH, Eiseman JL, Parise RA, Joseph E, Holleran JL, Covey JM, Egorin MJ (2006) Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice. Clin Cancer Res 12:7483-7491
3. Beumer JH, Parise RA, Newman EM, Doroshow JH, Synold TW, Lenz HJ, Egorin MJ (2008) Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Cancer Chemother Pharmacol 62:363-368
4. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, Pommier Y (2008) GammaH2AX and cancer. Nat Rev Cancer 8:957-967
5. Carey N, Marques CJ, Reik W (2011) DNA demethylases: a new epigenetic frontier in drug discovery. Drug Discov Today 16:683-690
6. Chuang JC, Yoo CB, Kwan JM, Li TW, Liang G, Yang AS, Jones PA (2005) Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine. Mol Cancer Ther 4:1515-1520
7. Cimprich KA, Cortez D (2008) ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 9:616-627
8. Ellis L, Atadja PW, Johnstone RW (2009) Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 8:1409-1420
9. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358:1148-1159
10. Gowher H, Jeltsch A (2004) Mechanism of inhibition of DNA methyltransferases by cytidine analogs in cancer therapy. Cancer Biol Ther 3:1062-1068
11. Jones PA, Taylor SM (1980) Cellular differentiation, cytidine analogs and DNA methylation. Cell 20:85-93
12. Kastan MB, Lim DS (2000) The many substrates and functions of ATM. Nat Rev Mol Cell Biol 1:179-186
13. Kratzke RA, Wang X, Wong L, Kratzke MG, Green MR, Vokes EE, Vogelzang NJ, Kindler HL, Kern JA (2008) Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904. J Thorac Oncol 3:417-421
14. Kruse JP, Gu W (2009) Modes of p53 regulation. Cell 137:609-622
15. Lord CJ, Ashworth A (2012) The DNA damage response and cancer therapy. Nature 481:287-294
16. Reither S, Li F, Gowher H, Jeltsch A (2003) Catalytic mechanism of DNA-(cytosine-C5)-methyltransferases revisited: covalent intermediate formation is not essential for methyl group transfer by the murine Dnmt3a enzyme. J Mol Biol 329:675-684
17. Ren J, Singh BN, Huang Q, Li Z, Gao Y, Mishra P, Hwa YL, Li J, Dowdy SC, Jiang SW (2011) DNA hypermethylation as a chemotherapy target. Cell Signal 23:1082-1093
18. Robertson KD (2005) DNA methylation and human disease. Nat Rev Genet 6:597-610
19. Royds JA, Iacopetta B (2006) p53 and disease: when the guardian angel fails. Cell Death Differ 13:1017-1026
20. Schar P (2001) Spontaneous DNA damage, genome instability, and cancer-when DNA replication escapes control. Cell 104:329-332
21. Speidel D (2010) Transcription-independent p53 apoptosis: an alternative route to death. Trends Cell Biol 20:14-24
22. Vousden KH, Prives C (2009) Blinded by the light: the growing complexity of p53. Cell 137:413-431
23. Wade M, Wang YV, Wahl GM (2010) The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 20:299-309